LAG3 and nonpapillary renal cell carcinoma: In addition, other checkpoint inhibitors, such as antibodies targeting T cell immunoglobulin (VISTA), mucin domain 3 (TIM-3), lymphocyte activation gene 3 (LAG-3), and TIGIT, are also being evaluated in clinical trials for the treatment of ccRCC [63].